BioCentury
ARTICLE | Clinical News

Merck's doravirine similar to ritonavir-boosted darunavir in Phase III for HIV-1 infection

August 3, 2018 4:56 PM UTC

Merck & Co. Inc. (NYSE:MRK) said once-daily oral doravirine (MK-1439) in combination with other antiretroviral therapies (ARTs) led to viral suppression at week 96 in 73.1% of patients vs. 66% of patients treated with ritonavir-boosted darunavir plus ARTs in the Phase III DRIVE-FORWARD (MK-1439-018) trial to treat HIV-1 infection in treatment-naïve patients. The company previously reported that doravirine plus ARTs met the primary endpoint of non-inferiority to ritonavir-boosted darunavir plus ARTs in the proportion of virally suppressed patients at week 48.

The double-blind, international trial enrolled 766 patients to receive once-daily 100 mg doravirine or darunavir plus ritonavir. Both arms also received investigator’s choice of emtricitabine plus tenofovir disoproxil fumarate or abacavir plus lamivudine. Viral suppression was defined as HIV RNA levels of <50 copies/mL...

BCIQ Company Profiles

Merck & Co. Inc.

BCIQ Target Profiles

HIV reverse transcriptase